eligibility_summary
Adults ≥18 with CD30+ (≥1%) T‑NHL (e.g., PTCL, AITL, ALCL, NK/T, CTCL), ECOG 0–1, R/R after ≥1 systemic therapy (Brentuximab allowed unless refractory or ≥G2 tox). PTCL needs measurable lesion, adequate organs, contraception. Exclude: prior PD‑1/PD‑L1/CTLA‑4, ATLL, recent tx/radiation/live vaccine/trial, pneumonitis/ILD, immunodeficiency/steroids, active autoimmune/infection, myocarditis/NYHA III–IV, active CNS mets, recent malignancy, pembro allergy, HIV/HBV/HCV, severe liver/psych/substance disease, TB, allo‑SCT <5y/GVHD, ≥G2 neuropathy, pregnancy/breastfeeding.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2 single-arm study testing: 1) Pembrolizumab—humanized IgG4 monoclonal antibody immune checkpoint inhibitor targeting PD-1, mechanism: blocks PD-1 on exhausted T cells, releasing PD-1/PD-L1 inhibitory signaling to restore antitumor cytotoxicity. 2) Brentuximab vedotin—anti-CD30 antibody-drug conjugate (ADC) linked to MMAE, mechanism: binds CD30 on malignant T cells, internalizes, releases MMAE to disrupt microtubules, causing G2/M arrest and apoptosis (possible bystander effect). Targets/pathways: CD30+ malignant T cells (PTCL, CTCL, NK/T), PD-1/PD-L1 checkpoint axis, and microtubule cytoskeleton. Regimen: 16 cycles combo, then pembrolizumab monotherapy to 35 total doses.